Telmisartan in the management of abdominal aortic aneurysm

Phase 2

• Conditions: Abdominal Aortic Aneurysm; Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system

• Registration Number: ACTRN12611000931976
• Lead Sponsor: James Cook University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-08-30
• Study Completion: 2018-10-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 208

Inclusion Criteria

1. Written informed consent 2. Infra-renal AAA measuring a maximum orthogonal diameter greater than or equal to 35mm and less than or equal to 49mm on CTA or ultrasound; 3. Stable medication regime for the last 6 months; 4. No current indication for AAA repair according to the treating physician or expectation that this will be revised within the next year; 5. High likelihood of compliance with treatment over 24 months.

Exclusion Criteria

Contraindications to study treatment, including: 1. renal impairment (i.e. creatinine >1.5x upper limit of normal [ULN]), 2. known significant renal stenosis (>70%) of one or both renal arteries, 3. chronic liver disease (i.e. cirrhosis or hepatitis) or abnormal liver function (i.e. ALT 1.5xULN), 4. electrolyte imbalance and 5. active gout; 6. Current or planned usage of an AT1 blocker 7. Current or planned usage of an ACE inhibitor. 8. If the patient has previously had abdominal aortic surgery

Study & Design

• Study Type: Interventional
• Study Design: Not specified